These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33427302)

  • 21. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
    Trinité B; Tarrés-Freixas F; Rodon J; Pradenas E; Urrea V; Marfil S; Rodríguez de la Concepción ML; Ávila-Nieto C; Aguilar-Gurrieri C; Barajas A; Ortiz R; Paredes R; Mateu L; Valencia A; Guallar V; Ruiz L; Grau E; Massanella M; Puig J; Chamorro A; Izquierdo-Useros N; Segalés J; Clotet B; Carrillo J; Vergara-Alert J; Blanco J
    Sci Rep; 2021 Jan; 11(1):2608. PubMed ID: 33510275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis.
    Lee E; Oh JE
    Mol Cells; 2021 Jun; 44(6):392-400. PubMed ID: 34059562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
    Grenache DG; Ye C; Bradfute SB
    J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Qu J; Wu C; Li X; Zhang G; Jiang Z; Li X; Zhu Q; Liu L
    Clin Infect Dis; 2020 Nov; 71(16):2255-2258. PubMed ID: 32337590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG.
    Schwarzkopf S; Krawczyk A; Knop D; Klump H; Heinold A; Heinemann FM; Thümmler L; Temme C; Breyer M; Witzke O; Dittmer U; Lenz V; Horn PA; Lindemann M
    Emerg Infect Dis; 2021 Jan; 27(1):. PubMed ID: 33058753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B careful: Humoral responses and COVID-19 severity.
    Fanous H; Guerrero-Pena A; Pillai A
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33277373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Responses One Year after Mild SARS-CoV-2 Infection.
    Choe PG; Kim KH; Kang CK; Suh HJ; Kang E; Lee SY; Kim NJ; Yi J; Park WB; Oh MD
    J Korean Med Sci; 2021 May; 36(21):e157. PubMed ID: 34060263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.
    Meschi S; Colavita F; Bordi L; Matusali G; Lapa D; Amendola A; Vairo F; Ippolito G; Capobianchi MR; Castilletti C;
    J Clin Virol; 2020 Aug; 129():104539. PubMed ID: 32679298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients.
    Ouoba S; Okimoto M; Nagashima S; Kitahara Y; Miwata K; Ko K; E B; Sugiyama A; Takahashi K; Sakaguchi T; Takafuta T; Tanaka J
    J Med Virol; 2022 Apr; 94(4):1734-1737. PubMed ID: 34897741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tissue culture infectious dose-derived protocol for testing of SARS-CoV-2 neutralization of serum antibodies on adherent cells.
    Hasler F; Duda A; Kündig TM; Johansen P
    STAR Protoc; 2021 Dec; 2(4):100824. PubMed ID: 34467223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced SARS-CoV-2 neutralization by dimeric IgA.
    Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Viant C; Gaebler C; Cipolla M; Hoffmann HH; Oliveira TY; Oren DA; Ramos V; Nogueira L; Michailidis E; Robbiani DF; Gazumyan A; Rice CM; Hatziioannou T; Bieniasz PD; Caskey M; Nussenzweig MC
    Sci Transl Med; 2021 Jan; 13(577):. PubMed ID: 33288661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Bahar B; Jacquot C; Mo YD; DeBiasi RL; Campos J; Delaney M
    J Pediatr; 2020 Dec; 227():31-37.e1. PubMed ID: 32891640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.
    Infantino M; Grossi V; Lari B; Bambi R; Perri A; Manneschi M; Terenzi G; Liotti I; Ciotta G; Taddei C; Benucci M; Casprini P; Veneziani F; Fabbri S; Pompetti A; Manfredi M
    J Med Virol; 2020 Sep; 92(9):1671-1675. PubMed ID: 32330291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.
    Manenti A; Maggetti M; Casa E; Martinuzzi D; Torelli A; Trombetta CM; Marchi S; Montomoli E
    J Med Virol; 2020 Oct; 92(10):2096-2104. PubMed ID: 32383254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy.
    Rondinone V; Pace L; Fasanella A; Manzulli V; Parisi A; Capobianchi MR; Ostuni A; Chironna M; Caprioli E; Labonia M; Cipolletta D; Della Rovere I; Serrecchia L; Petruzzi F; Pennuzzi G; Galante D
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33670182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019.
    Noh JY; Kwak JE; Yang JS; Hwang SY; Yoon JG; Seong H; Hyun H; Lim CS; Yoon SY; Ryou J; Lee JY; Kim SS; Park SH; Cheong HJ; Kim WJ; Shin EC; Song JY
    J Infect Dis; 2021 Sep; 224(5):754-763. PubMed ID: 34467985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.
    Vanderheiden A; Edara VV; Floyd K; Kauffman RC; Mantus G; Anderson E; Rouphael N; Edupuganti S; Shi PY; Menachery VD; Wrammert J; Suthar MS
    Curr Protoc Immunol; 2020 Dec; 131(1):e116. PubMed ID: 33215858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers.
    Bonfante F; Costenaro P; Cantarutti A; Di Chiara C; Bortolami A; Petrara MR; Carmona F; Pagliari M; Cosma C; Cozzani S; Mazzetto E; Di Salvo G; Da Dalt L; Palma P; Barzon L; Corrao G; Terregino C; Padoan A; Plebani M; De Rossi A; Donà D; Giaquinto C
    Pediatrics; 2021 Sep; 148(3):. PubMed ID: 34158312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of humoral immune responses against SARS-CoV-2 accessory proteins in infected patients and mouse model.
    Li Y; Tang Y; Wang X; Zhu A; Liu D; He Y; Guo H; Zheng J; Liu X; Chi F; Wang Y; Zhuang Z; Zhang Z; Liu D; Chen Z; Li F; Ran W; Yu K; Wang D; Wen L; Zhuo J; Zhang Y; Xi Y; Zhao J; Zhao J; Sun J
    Virol Sin; 2024 Jun; 39(3):414-421. PubMed ID: 38677713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.